Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.7K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.7K
Negative Regulator Molecules01:23

Negative Regulator Molecules

37.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
37.5K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.7K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.7K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

7.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.5K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

10.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of circadian clock activators with anti-obesity efficacy via suppression of adipocyte development and hypertrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

AI-Driven Design of High Affinity Biomolecule-Drug Conjugates for Gynecological Cancer Therapy: An Up-to-Date Narrative Review.

Cancers·2026
Same author

Fatty acid-activated proton transporter SR4 prevents hepatic steatosis and metabolic alterations in diabetic mice by improving mitochondria function, energy balance and oxidative stress.

Experimental and therapeutic medicine·2026
Same author

Engineering nanozymes for cancer theranostics: Chemical design, catalytic intelligence, and translational oncology frontiers.

Translational oncology·2026
Same author

Inflammation-driven transcriptional reprogramming in prostate cancer: Convergence of NFκB, JAK/STAT3, and epigenetic remodeling in castration-resistant disease.

Cancer letters·2026
Same author

The Potent Complement Stimulus of Sanguineous Versus Crystalloid Cardiopulmonary Bypass Prime during Pediatric Cardiac Surgery.

World journal for pediatric & congenital heart surgery·2026
Same journal

Macropinocytosis: A central orchestrator in tumor development and therapeutic resistance.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

KIAA0101 in human cancers: From biomarker discovery to therapeutic targeting.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Post-translational modifications as hubs of amino acid metabolism in cancer: From oncogenic signaling to therapeutic targeting.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Senescence in non-cancerous cells within the tumor: What is the real deal?

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

The MYC network: Hub of malignancy and blueprint for intervention.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer.

Biochimica et biophysica acta. Reviews on cancer·2026
See all related articles

Related Experiment Video

Updated: Nov 21, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K

Activating p53 function by targeting RLIP.

Sharad S Singhal1, David Horne2, Jyotsana Singhal1

  • 1Department of Medical Oncology, Beckman Research Institute, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA.

Biochimica Et Biophysica Acta. Reviews on Cancer
|January 18, 2021
PubMed
Summary
This summary is machine-generated.

Aberrations in RLIP, p53, and PKCα are key to cancer. Partial RLIP depletion in p53-deficient mice prevents tumors, revealing crucial cross-talk for cancer prevention and therapy.

Keywords:
Drug resistanceGlutathione-electrophile conjugateMercapturic acid pathwayMetastasisPKCαRLIPRalBP1Therapeuticsp53

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.4K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

571

Related Experiment Videos

Last Updated: Nov 21, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.8K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.4K
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

571

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Aberrations in RLIP, p53, and PKCα are central to human neoplasms.
  • Dysfunctional p53, elevated PKCα, and altered glutathione (GSH) metabolism drive carcinogenesis and resistance.
  • Limited understanding of these interactions hinders cancer prevention and therapy development.

Purpose of the Study:

  • To explore the cross-talk between p53, PKCα, and GSH signaling mediated by RLIP in cancer.
  • To investigate the role of RLIP in carcinogenesis and drug/radiation resistance.
  • To present a novel hypothesis on the interaction of these key regulatory nodes.

Main Methods:

  • Review of existing literature on RLIP, p53, and PKCα in cancer models.
  • Analysis of findings in p53-/- rodent models with genetic manipulation of RLIP.
  • Examination of RLIP-/- mice for alterations in p53, PKCα, and carcinogenesis resistance.

Main Results:

  • RLIP overexpression enhances cancer proliferation and resistance; RLIP depletion causes tumor regression.
  • Partial RLIP depletion in p53-/- mice confers complete protection from neoplasia.
  • RLIP-/- mice show altered p53 and PKCα function, impaired clathrin-dependent endocytosis, and resistance to chemical carcinogenesis.

Conclusions:

  • RLIP is a critical effector of p53, involved in cancer-promoting epigenetic remodeling.
  • A novel hypothesis suggests significant cross-talk between p53, PKCα, and GSH signaling via RLIP.
  • Understanding this interplay is crucial for developing novel cancer prevention and therapeutic strategies.